$ABVX terrific work but IMO Scorp has likely already largely exited this position. They may retain a small position to say "we are short". The real goal is a "wham bam, thank you biotwitter," move and then onto the next target. Scientific accuracy is not particularly important in all of this.
Replying to @AdamYusimBio
Start with the single biggest pharmacokinetic sleight of hand in the entire report (page 112).
Scorpion calculates parent obefazimod's apparent volume of distribution (V/F) at 1,228 L, roughly 29x total body water. $ABVX
3
80
$ZROZ it's time
A tone deaf and backward-looking Fed is putting financial stability at risk. The VIX is now at higher levels than on a comparable scale in 2022 when we had lots of Fed hikes and high oil prices. That just shows how much damage the Fed is causing now...
robinjbrooks.substack.com/p/…
1
207
$XBI One of the smarter things I've read here on X.
Commodities are getting hit pretty hard alongside the broader equity market as the surging U.S. dollar sucks liquidity out of the global financial system. For those that follow me, I've been saying this from some time that there was risks if the dollar strengthens too quickly.
The issue is that dollar-denominated debt becomes more expensive to service, financial conditions tighten, and investors are forced to raise cash, reduce leverage and sell assets. It becomes less about fundamentals and more about liquidity.
One thing I've learned over the years is that market leverage doesn't necessarily tell you when a correction will happen, but it tells you a great deal about how painful that correction could become. For some perspective, U.S. margin debt has surged to approximately $1.45 trillion, equivalent to roughly 58% of U.S. currency in circulation and 6.2% of M2 money supply. That's an extraordinary amount of leverage in the system, and when markets start moving against investors, it can accelerate the selling pressure.
Unfortunately, even gold isn't immune. During a liquidity-driven selloff, investors often sell what they can, not necessarily what they want to. Gold can become a source of cash to cover margin calls and offset losses elsewhere.
The irony is that the very forces driving the dollar higher could eventually create the conditions for its reversal. The U.S. government and broader financial system have become increasingly reliant on negative real interest rates to help manage an enormous debt burden. A prolonged dollar-driven liquidity squeeze makes that increasingly difficult, raising the risk that something eventually breaks and forces central banks to step in with lower rates and additional liquidity.
That's when things can get interesting for gold. It may get sold during the initial panic, but if policymakers respond by driving real interest rates back into negative territory, the combination of easier money and renewed currency debasement concerns could send gold sharply higher.
In other words, the same liquidity squeeze hurting gold today could ultimately create the conditions for its next rally.
We're watching all of this closely and remaining deliberate about managing exposure through what continues to be a challenging market environment through to the end of the year.
2
709
$ABVX meant "should be illegal" here. Hyped up on coffee and typing too fast
$ABVX this really shouldn't be illegal. You put your short positions in place, then issue a "short report", creating serious FUD, driving down the stock temporarily, just long enough for you to cover at a nice profit. You really don't care whether the drug works, the plan is to make your money quickly with a body slam.
3
454
$ABVX this really shouldn't be illegal. You put your short positions in place, then issue a "short report", creating serious FUD, driving down the stock temporarily, just long enough for you to cover at a nice profit. You really don't care whether the drug works, the plan is to make your money quickly with a body slam.
$ABVX I have a strong debt of gratitude to @ScorpionFund for the entry today.
20
710
$ABVX The clearest rebuttal is ABTECT-2. The report implies obefazimod’s Phase 3 efficacy depended on questionable Chinese sites. ABTECT-2 enrolled 636 patients across 27 countries, with no listed sites in China, and the 50 mg dose beat placebo on week-eight clinical remission by 13.4 percentage points (p = 0.0001).
9
1,258
$ABVX I'll trust @Biohazard3737 and @A_May_MD and @BayAreaBiotechI any day versus @ScorpionFund. In the end this one will work out just fine.
1
25
1,307
$INSM Insmed Stock Is a Winner With or Without a Sanofi Buyout, Analysts Say barrons.com/articles/insmed-… via @BarronsOnline
The master plan. Target V02 max.
Scientists tested a cyclist at age 101 and again at 103.
- VO2 max: 31 → 35 mL/kg/min (+13%)
- Peak power: 90 → 125 W (+39%)
- Max pedaling cadence: 69 → 90 rpm (+30%)
- One-hour cycling record: 24.25 → 26.92 km (+11%)
His name was Robert Marchand, and he set the 1-hour cycling records for both the 100–104 and 105+ age groups. He died at age 109.
Between the two lab tests, he rode about 5000 km/year, and 80% of that was easy.
PMID: 28035015
1
337
$COGT well, well. I have some good company on this one.
2
16
2,064
Osprey Cap II retweeted
$HELP on the clinical profile: responder and remission rates profile appear very compelling. Early onset too. Evident as early as "the day after dosing".
Major grifter.
Greta Thunberg has officially moved on from saving the planet
This is her dancing in a "Ship to Gaza" shirt. And this week she burst out laughing when she was told Fridays for Future, the climate movement she started at 15, was still protesting in Berlin. "Really? They still do that?"
Millions of kids walked out of school because of her. Now the climate is old news and she's on to the next cause
It was NEVER about the climate
2
715
$HELP IMO the data meaningfully strengthens the case for HLP003 as a potential MDD treatment. Efficacy of this magnitude could support substantial commercial value. Cross trial comparisons are tough, of course. Compass studied treatment resisitant depression while Helus studied moderate to severe. Caplyta's comparison is arguably the better comparison. J&J has described Caplyta's potential at more than $5 billion (across multiple indications including MDD).
7
1,276
$HELP I agree the headline data looks very strong. a 7.6 point advantage over placebo at 6 weeks and 7.0 maintained at twelve weeks is impressive in a phase 3 depression result. Helus' separation is twice Compass's and approximately 55-60% larger than Caplyta's.
$HELP Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in MDD
-7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the MADRS (p< 0.0001)
$HELP Since August 31, four senior executives and directors have collectively purchased approximately 788,000 shares for $9.7 million in the open market, including:
- Eric So, Executive Chairman: 295,000 shares / $3.57 million
- Paul Glavine, Chief Growth Officer: 390,000 shares / $4.72 million
- Michael Halstead, CEO: 100,000 shares / $1.35 million
- Greg Cavers, CFO: 3,000 shares / $38,730
These are open-market purchases made with personal capital, not stock grants or option exercises.
8:20 AM
12
1,214
















